PMC:7288617 / 4067-5692 JSON TXT

Annnotations TAB JSON ListView MergeView

LitCovid-PD-FMA-UBERON

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T25","span":{"begin":63,"end":66},"obj":"Body_part"},{"id":"T26","span":{"begin":401,"end":415},"obj":"Body_part"},{"id":"T27","span":{"begin":985,"end":1001},"obj":"Body_part"},{"id":"T28","span":{"begin":1522,"end":1536},"obj":"Body_part"}],"attributes":[{"id":"A25","pred":"fma_id","subj":"T25","obj":"http://purl.org/sig/ont/fma/fma20935"},{"id":"A26","pred":"fma_id","subj":"T26","obj":"http://purl.org/sig/ont/fma/fma62871"},{"id":"A27","pred":"fma_id","subj":"T27","obj":"http://purl.org/sig/ont/fma/fma50866"},{"id":"A28","pred":"fma_id","subj":"T28","obj":"http://purl.org/sig/ont/fma/fma62871"}],"text":"Discussion\nThe clinical presentation of the reported case, and CSF analysis showing a picture of albumin-cytological dissociation, suggested the diagnosis of MFS as previously described in the literature (Wakerley et al. 2014). The novelty of this case is represented by the diagnosis of MFS in a COVID-19 patient and by the clinical suggestion of treating neurological complications with intravenous immunoglobulin therapy. Such neurological complications are common in respiratory infections (Sellers et al. 2017); therefore, a cross-reactivity also for the new SARS-CoV-2 was speculated and reported (Zhao et al. 2020) as for SARS-CoV affected patients (Baig et al. 2020). We did not find any presence of anti-GQ1b, usually explaining the symptoms of the disease (Wakerley et al. 2014). However, negative results for anti-GQ1b tests have been previously reported (Wattanasit and Sathirapanya 2020). The particular cranial polyradiculoneuritis with the involvement of the facial and trigeminal nerve is well-known in MFS and MFS variants (Polo et al. 1992; Wakerley et al. 2014), and in the reported case, it was found being associated to an altered sense of taste, which is an uncommon feature of MFS but well-reported in COVID-19. IVIG was found to be effective and safe to treat the reported neurological symptoms, showing complete recovery after 7 days. In conclusion, this case report describes the characteristics of a MFS/cranial polyneuritis in a patient with COVID-19, and the clinical responses to intravenous immunoglobulin therapy, suggesting possible diagnosis and treatment options in this peculiar condition."}

LitCovid-PD-UBERON

{"project":"LitCovid-PD-UBERON","denotations":[{"id":"T11","span":{"begin":985,"end":1001},"obj":"Body_part"},{"id":"T12","span":{"begin":996,"end":1001},"obj":"Body_part"}],"attributes":[{"id":"A11","pred":"uberon_id","subj":"T11","obj":"http://purl.obolibrary.org/obo/UBERON_0001645"},{"id":"A12","pred":"uberon_id","subj":"T12","obj":"http://purl.obolibrary.org/obo/UBERON_0001021"}],"text":"Discussion\nThe clinical presentation of the reported case, and CSF analysis showing a picture of albumin-cytological dissociation, suggested the diagnosis of MFS as previously described in the literature (Wakerley et al. 2014). The novelty of this case is represented by the diagnosis of MFS in a COVID-19 patient and by the clinical suggestion of treating neurological complications with intravenous immunoglobulin therapy. Such neurological complications are common in respiratory infections (Sellers et al. 2017); therefore, a cross-reactivity also for the new SARS-CoV-2 was speculated and reported (Zhao et al. 2020) as for SARS-CoV affected patients (Baig et al. 2020). We did not find any presence of anti-GQ1b, usually explaining the symptoms of the disease (Wakerley et al. 2014). However, negative results for anti-GQ1b tests have been previously reported (Wattanasit and Sathirapanya 2020). The particular cranial polyradiculoneuritis with the involvement of the facial and trigeminal nerve is well-known in MFS and MFS variants (Polo et al. 1992; Wakerley et al. 2014), and in the reported case, it was found being associated to an altered sense of taste, which is an uncommon feature of MFS but well-reported in COVID-19. IVIG was found to be effective and safe to treat the reported neurological symptoms, showing complete recovery after 7 days. In conclusion, this case report describes the characteristics of a MFS/cranial polyneuritis in a patient with COVID-19, and the clinical responses to intravenous immunoglobulin therapy, suggesting possible diagnosis and treatment options in this peculiar condition."}

LitCovid-PD-MONDO

LitCovid-PD-CLO

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T46","span":{"begin":84,"end":85},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T47","span":{"begin":295,"end":296},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T48","span":{"begin":528,"end":529},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T49","span":{"begin":830,"end":835},"obj":"http://purl.obolibrary.org/obo/UBERON_0000473"},{"id":"T50","span":{"begin":996,"end":1001},"obj":"http://purl.obolibrary.org/obo/UBERON_0001021"},{"id":"T51","span":{"begin":1425,"end":1426},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T52","span":{"begin":1455,"end":1456},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"}],"text":"Discussion\nThe clinical presentation of the reported case, and CSF analysis showing a picture of albumin-cytological dissociation, suggested the diagnosis of MFS as previously described in the literature (Wakerley et al. 2014). The novelty of this case is represented by the diagnosis of MFS in a COVID-19 patient and by the clinical suggestion of treating neurological complications with intravenous immunoglobulin therapy. Such neurological complications are common in respiratory infections (Sellers et al. 2017); therefore, a cross-reactivity also for the new SARS-CoV-2 was speculated and reported (Zhao et al. 2020) as for SARS-CoV affected patients (Baig et al. 2020). We did not find any presence of anti-GQ1b, usually explaining the symptoms of the disease (Wakerley et al. 2014). However, negative results for anti-GQ1b tests have been previously reported (Wattanasit and Sathirapanya 2020). The particular cranial polyradiculoneuritis with the involvement of the facial and trigeminal nerve is well-known in MFS and MFS variants (Polo et al. 1992; Wakerley et al. 2014), and in the reported case, it was found being associated to an altered sense of taste, which is an uncommon feature of MFS but well-reported in COVID-19. IVIG was found to be effective and safe to treat the reported neurological symptoms, showing complete recovery after 7 days. In conclusion, this case report describes the characteristics of a MFS/cranial polyneuritis in a patient with COVID-19, and the clinical responses to intravenous immunoglobulin therapy, suggesting possible diagnosis and treatment options in this peculiar condition."}

LitCovid-PD-CHEBI

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T24","span":{"begin":713,"end":717},"obj":"Chemical"},{"id":"T25","span":{"begin":825,"end":829},"obj":"Chemical"},{"id":"T26","span":{"begin":1041,"end":1045},"obj":"Chemical"}],"attributes":[{"id":"A24","pred":"chebi_id","subj":"T24","obj":"http://purl.obolibrary.org/obo/CHEBI_27515"},{"id":"A25","pred":"chebi_id","subj":"T25","obj":"http://purl.obolibrary.org/obo/CHEBI_27515"},{"id":"A26","pred":"chebi_id","subj":"T26","obj":"http://purl.obolibrary.org/obo/CHEBI_39299"}],"text":"Discussion\nThe clinical presentation of the reported case, and CSF analysis showing a picture of albumin-cytological dissociation, suggested the diagnosis of MFS as previously described in the literature (Wakerley et al. 2014). The novelty of this case is represented by the diagnosis of MFS in a COVID-19 patient and by the clinical suggestion of treating neurological complications with intravenous immunoglobulin therapy. Such neurological complications are common in respiratory infections (Sellers et al. 2017); therefore, a cross-reactivity also for the new SARS-CoV-2 was speculated and reported (Zhao et al. 2020) as for SARS-CoV affected patients (Baig et al. 2020). We did not find any presence of anti-GQ1b, usually explaining the symptoms of the disease (Wakerley et al. 2014). However, negative results for anti-GQ1b tests have been previously reported (Wattanasit and Sathirapanya 2020). The particular cranial polyradiculoneuritis with the involvement of the facial and trigeminal nerve is well-known in MFS and MFS variants (Polo et al. 1992; Wakerley et al. 2014), and in the reported case, it was found being associated to an altered sense of taste, which is an uncommon feature of MFS but well-reported in COVID-19. IVIG was found to be effective and safe to treat the reported neurological symptoms, showing complete recovery after 7 days. In conclusion, this case report describes the characteristics of a MFS/cranial polyneuritis in a patient with COVID-19, and the clinical responses to intravenous immunoglobulin therapy, suggesting possible diagnosis and treatment options in this peculiar condition."}

LitCovid-PD-GO-BP

{"project":"LitCovid-PD-GO-BP","denotations":[{"id":"T2","span":{"begin":1152,"end":1166},"obj":"http://purl.obolibrary.org/obo/GO_0050909"}],"text":"Discussion\nThe clinical presentation of the reported case, and CSF analysis showing a picture of albumin-cytological dissociation, suggested the diagnosis of MFS as previously described in the literature (Wakerley et al. 2014). The novelty of this case is represented by the diagnosis of MFS in a COVID-19 patient and by the clinical suggestion of treating neurological complications with intravenous immunoglobulin therapy. Such neurological complications are common in respiratory infections (Sellers et al. 2017); therefore, a cross-reactivity also for the new SARS-CoV-2 was speculated and reported (Zhao et al. 2020) as for SARS-CoV affected patients (Baig et al. 2020). We did not find any presence of anti-GQ1b, usually explaining the symptoms of the disease (Wakerley et al. 2014). However, negative results for anti-GQ1b tests have been previously reported (Wattanasit and Sathirapanya 2020). The particular cranial polyradiculoneuritis with the involvement of the facial and trigeminal nerve is well-known in MFS and MFS variants (Polo et al. 1992; Wakerley et al. 2014), and in the reported case, it was found being associated to an altered sense of taste, which is an uncommon feature of MFS but well-reported in COVID-19. IVIG was found to be effective and safe to treat the reported neurological symptoms, showing complete recovery after 7 days. In conclusion, this case report describes the characteristics of a MFS/cranial polyneuritis in a patient with COVID-19, and the clinical responses to intravenous immunoglobulin therapy, suggesting possible diagnosis and treatment options in this peculiar condition."}

LitCovid-PD-GlycoEpitope

{"project":"LitCovid-PD-GlycoEpitope","denotations":[{"id":"T8","span":{"begin":713,"end":717},"obj":"GlycoEpitope"},{"id":"T9","span":{"begin":825,"end":829},"obj":"GlycoEpitope"}],"attributes":[{"id":"A8","pred":"glyco_epitope_db_id","subj":"T8","obj":"http://www.glycoepitope.jp/epitopes/EP0069"},{"id":"A9","pred":"glyco_epitope_db_id","subj":"T9","obj":"http://www.glycoepitope.jp/epitopes/EP0069"}],"text":"Discussion\nThe clinical presentation of the reported case, and CSF analysis showing a picture of albumin-cytological dissociation, suggested the diagnosis of MFS as previously described in the literature (Wakerley et al. 2014). The novelty of this case is represented by the diagnosis of MFS in a COVID-19 patient and by the clinical suggestion of treating neurological complications with intravenous immunoglobulin therapy. Such neurological complications are common in respiratory infections (Sellers et al. 2017); therefore, a cross-reactivity also for the new SARS-CoV-2 was speculated and reported (Zhao et al. 2020) as for SARS-CoV affected patients (Baig et al. 2020). We did not find any presence of anti-GQ1b, usually explaining the symptoms of the disease (Wakerley et al. 2014). However, negative results for anti-GQ1b tests have been previously reported (Wattanasit and Sathirapanya 2020). The particular cranial polyradiculoneuritis with the involvement of the facial and trigeminal nerve is well-known in MFS and MFS variants (Polo et al. 1992; Wakerley et al. 2014), and in the reported case, it was found being associated to an altered sense of taste, which is an uncommon feature of MFS but well-reported in COVID-19. IVIG was found to be effective and safe to treat the reported neurological symptoms, showing complete recovery after 7 days. In conclusion, this case report describes the characteristics of a MFS/cranial polyneuritis in a patient with COVID-19, and the clinical responses to intravenous immunoglobulin therapy, suggesting possible diagnosis and treatment options in this peculiar condition."}

LitCovid-PD-HP

{"project":"LitCovid-PD-HP","denotations":[{"id":"T24","span":{"begin":471,"end":493},"obj":"Phenotype"},{"id":"T25","span":{"begin":1439,"end":1451},"obj":"Phenotype"}],"attributes":[{"id":"A24","pred":"hp_id","subj":"T24","obj":"http://purl.obolibrary.org/obo/HP_0011947"},{"id":"A25","pred":"hp_id","subj":"T25","obj":"http://purl.obolibrary.org/obo/HP_0031003"}],"text":"Discussion\nThe clinical presentation of the reported case, and CSF analysis showing a picture of albumin-cytological dissociation, suggested the diagnosis of MFS as previously described in the literature (Wakerley et al. 2014). The novelty of this case is represented by the diagnosis of MFS in a COVID-19 patient and by the clinical suggestion of treating neurological complications with intravenous immunoglobulin therapy. Such neurological complications are common in respiratory infections (Sellers et al. 2017); therefore, a cross-reactivity also for the new SARS-CoV-2 was speculated and reported (Zhao et al. 2020) as for SARS-CoV affected patients (Baig et al. 2020). We did not find any presence of anti-GQ1b, usually explaining the symptoms of the disease (Wakerley et al. 2014). However, negative results for anti-GQ1b tests have been previously reported (Wattanasit and Sathirapanya 2020). The particular cranial polyradiculoneuritis with the involvement of the facial and trigeminal nerve is well-known in MFS and MFS variants (Polo et al. 1992; Wakerley et al. 2014), and in the reported case, it was found being associated to an altered sense of taste, which is an uncommon feature of MFS but well-reported in COVID-19. IVIG was found to be effective and safe to treat the reported neurological symptoms, showing complete recovery after 7 days. In conclusion, this case report describes the characteristics of a MFS/cranial polyneuritis in a patient with COVID-19, and the clinical responses to intravenous immunoglobulin therapy, suggesting possible diagnosis and treatment options in this peculiar condition."}

LitCovid-sentences

{"project":"LitCovid-sentences","denotations":[{"id":"T29","span":{"begin":0,"end":10},"obj":"Sentence"},{"id":"T30","span":{"begin":11,"end":220},"obj":"Sentence"},{"id":"T31","span":{"begin":221,"end":227},"obj":"Sentence"},{"id":"T32","span":{"begin":228,"end":424},"obj":"Sentence"},{"id":"T33","span":{"begin":425,"end":509},"obj":"Sentence"},{"id":"T34","span":{"begin":510,"end":615},"obj":"Sentence"},{"id":"T35","span":{"begin":616,"end":668},"obj":"Sentence"},{"id":"T36","span":{"begin":669,"end":675},"obj":"Sentence"},{"id":"T37","span":{"begin":676,"end":782},"obj":"Sentence"},{"id":"T38","span":{"begin":783,"end":789},"obj":"Sentence"},{"id":"T39","span":{"begin":790,"end":901},"obj":"Sentence"},{"id":"T40","span":{"begin":902,"end":1052},"obj":"Sentence"},{"id":"T41","span":{"begin":1053,"end":1074},"obj":"Sentence"},{"id":"T42","span":{"begin":1075,"end":1234},"obj":"Sentence"},{"id":"T43","span":{"begin":1235,"end":1359},"obj":"Sentence"},{"id":"T44","span":{"begin":1360,"end":1625},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Discussion\nThe clinical presentation of the reported case, and CSF analysis showing a picture of albumin-cytological dissociation, suggested the diagnosis of MFS as previously described in the literature (Wakerley et al. 2014). The novelty of this case is represented by the diagnosis of MFS in a COVID-19 patient and by the clinical suggestion of treating neurological complications with intravenous immunoglobulin therapy. Such neurological complications are common in respiratory infections (Sellers et al. 2017); therefore, a cross-reactivity also for the new SARS-CoV-2 was speculated and reported (Zhao et al. 2020) as for SARS-CoV affected patients (Baig et al. 2020). We did not find any presence of anti-GQ1b, usually explaining the symptoms of the disease (Wakerley et al. 2014). However, negative results for anti-GQ1b tests have been previously reported (Wattanasit and Sathirapanya 2020). The particular cranial polyradiculoneuritis with the involvement of the facial and trigeminal nerve is well-known in MFS and MFS variants (Polo et al. 1992; Wakerley et al. 2014), and in the reported case, it was found being associated to an altered sense of taste, which is an uncommon feature of MFS but well-reported in COVID-19. IVIG was found to be effective and safe to treat the reported neurological symptoms, showing complete recovery after 7 days. In conclusion, this case report describes the characteristics of a MFS/cranial polyneuritis in a patient with COVID-19, and the clinical responses to intravenous immunoglobulin therapy, suggesting possible diagnosis and treatment options in this peculiar condition."}

LitCovid-PubTator

2_test

{"project":"2_test","denotations":[{"id":"32529516-25072194-63346690","span":{"begin":221,"end":225},"obj":"25072194"},{"id":"32529516-28745014-63346691","span":{"begin":510,"end":514},"obj":"28745014"},{"id":"32529516-32246917-63346692","span":{"begin":616,"end":620},"obj":"32246917"},{"id":"32529516-32167747-63346693","span":{"begin":669,"end":673},"obj":"32167747"},{"id":"32529516-25072194-63346694","span":{"begin":783,"end":787},"obj":"25072194"},{"id":"32529516-32231550-63346695","span":{"begin":895,"end":899},"obj":"32231550"},{"id":"32529516-1318358-63346696","span":{"begin":1053,"end":1057},"obj":"1318358"},{"id":"32529516-25072194-63346697","span":{"begin":1075,"end":1079},"obj":"25072194"}],"text":"Discussion\nThe clinical presentation of the reported case, and CSF analysis showing a picture of albumin-cytological dissociation, suggested the diagnosis of MFS as previously described in the literature (Wakerley et al. 2014). The novelty of this case is represented by the diagnosis of MFS in a COVID-19 patient and by the clinical suggestion of treating neurological complications with intravenous immunoglobulin therapy. Such neurological complications are common in respiratory infections (Sellers et al. 2017); therefore, a cross-reactivity also for the new SARS-CoV-2 was speculated and reported (Zhao et al. 2020) as for SARS-CoV affected patients (Baig et al. 2020). We did not find any presence of anti-GQ1b, usually explaining the symptoms of the disease (Wakerley et al. 2014). However, negative results for anti-GQ1b tests have been previously reported (Wattanasit and Sathirapanya 2020). The particular cranial polyradiculoneuritis with the involvement of the facial and trigeminal nerve is well-known in MFS and MFS variants (Polo et al. 1992; Wakerley et al. 2014), and in the reported case, it was found being associated to an altered sense of taste, which is an uncommon feature of MFS but well-reported in COVID-19. IVIG was found to be effective and safe to treat the reported neurological symptoms, showing complete recovery after 7 days. In conclusion, this case report describes the characteristics of a MFS/cranial polyneuritis in a patient with COVID-19, and the clinical responses to intravenous immunoglobulin therapy, suggesting possible diagnosis and treatment options in this peculiar condition."}

PMC:7288617 / 4067-5692 JSONTXT

Annnotations TAB JSON ListView MergeView

PMC:7288617 / 4067-5692 JSON TXT